Quest Diagnostics Rolls Out New Gene Expression Test for Melanoma risk Assessment
Quest Diagnostics is rolling out MelaNodal Predict, a predictive gene expression test that can help personalize treatment decisions melanoma patients. Dermatologists and other providers nationwide may begin ordering the test today from Quest Diagnostics, as well as through Dermpath Diagnostics, Quest’s subspecialty pathology business. MelaNodal Predict is based on technology developed by SkylineDx and the Mayo […]
Introducing TDD’s New Editorial Advisory Board
Drum roll, please…The Derm Digest is proud to announce the newest members of its Editorial Advisory Board. Joining the inaugural editorial board are… Christopher Bunick, MD, PhD Dr. Bunick is an associate professor of dermatology at Yale University in New Haven, CT. Raj Chovatiya, MD, PhD Dr. Chovatiya is the Founder and Director of the […]
Non-Lesional Filaggrin Expression May Predict Asthma in Kids With AD
Low filaggrin (FLG) expression in children aged 2 to 3 may predict of school-age asthma, according to new research slated to be presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting, in Washington, DC. In the study, pulmonary function testing (PFT) was conducted in 96 children, aged 7 to 8 years old, […]
First Patient Dosed in Artax’s Phase 2a Psoriasis Trial Evaluating AX-158
The first patient has been dosed in the Artax’s Phase 2a trial evaluating the safety and biomarker responses of AX-158 in a first proof of mechanism trial in psoriasis. AX-158 has potential to be the first immunomodulator in the Nck blocker class, the Company states. Safety and efficacy results are expected in second half of 2024. “The new Nck […]